Navigation Links
Three Hundred Scientists Meet in Miami to Work on a HIV Cure
Date:12/3/2015

According to WHO, HIV worldwide chronically infects 35 million individuals. Despite major advances in antiretroviral therapy over the last 2 decades, HIV persists in a latent state and infection rekindles each time antiretrovirals are stopped. This is explained by the persistence despite therapy of cells that act as viral reservoirs.

Currently, only one patient has been cured from HIV infection, the Berlin patient, who received a bone marrow transplant from a donor resistant to HIV due to a mutation on a gene coding for a co-receptor needed by HIV to infect cells (N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905).

However, several groups have described patients who received antiretroviral therapy at the time of acute infection and remained aviremic when antiretrovirals were stopped, a situation called HIV remission (PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211).

It is important to put forward research for HIV cure or remission as life-long antiretroviral therapy for 35 million people brings problems of access and cost.

The 7th International Workshop on HIV Persistence during Therapy will take place in Miami, Fl, on December 8-11, 2015 at the Marriott Biscayne Bay hotel. Three hundred participants are registered and will discuss their research on the topics of HIV reservoirs and HIV cure. Science and presentation of new, yet unpublished data, will drive this event.

The first day of the workshop will hold a session on the three Martin Delaney Collaboratories, the research programs initiated by the National Institute of Allergy and Infectious Diseases (NIAID). It will be followed by an opening lecture given by Carl Dieffenbach, Director of the NIAID.

During the 3 following days, the sessions will go from basic science to clinical applications (program attached). Each time, a key opinion leader will summarize the field knowledge, followed by oral presentation selected from abstracts submitted by the participants.

"We expect this workshop to be a turning point for HIV reservoirs knowledge and the search for a cure", Doctor Alain Lafeuillade said, one of the 4 members of the Steering Committee together with David Margolis (Chapel Hill), Mario Stevenson (Miami) and Karl Salzwedel (Bethesda)

Media are welcome to meet and interview Scientists during the workshop. Please call the contact number given below.

The 7th International Workshop on HIV Persistence during Therapy is supported by the NIH (National Institutes of Health), the NIAID, the AmFar (American Foundation for AIDS Research) and the ANRS (French Agency for AIDS Research). It is also organized with the help of the University of Miami and the University of Massachusetts.

Press contact:
Alain Lafeuillade, MD, member of the Steering Committee
Ph: +33 7 82513683

Read the full story at http://www.prweb.com/releases/2015/12/prweb13108504.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. The CCDC Launches the Cambridge Structural Database 2016 and Three Exciting New Software Suites
2. Paradigm Expands Access to PCDx Personalized Medicine Service by Signing Contract with Three Rivers Provider Network
3. Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions
4. Three Ways Translation Can Help Businesses Grow
5. MicroBiome Therapeutics Reports Advances In Three Microbiome Modulator Programs As It Launches Series B Financing
6. Surgical Specialties Corporation Awarded Three Year Suture Products Agreement with Premier, Inc.
7. Three companies meet the Vision4Mars Challenge with game-changing eye healthcare technologies for astronauts
8. Digital Agency StudioPMG Earns Three More MarCom Awards
9. OncoGenex Announces Relocation of Corporate Headquarters, Expected to Yield Savings of at Least $4 Million Over Next Three Years
10. Origin Agritech Limited Reports Unaudited Financial Results For Three Months Ended December 31, 2014 and Announces its First United States Patent Application
11. ITRA Global Hosts CEO Panel to Explain Why Utah Ranks as the Top Pro-Business State Three Years in a Row
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2018)... BUFFALO, N.Y. (PRWEB) , ... July 31, 2018 ... ... release of 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD ... molecular quality controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed ...
(Date:7/25/2018)... , ... July 25, 2018 , ... ... biofield energy treated proprietary nutraceutical to combat inflammation and autoimmune disorders. , ... immune function response. The following data was reported:, ...
(Date:7/24/2018)... (PRWEB) , ... July 23, 2018 , ... ... of a biofield energy treated nutraceutical to increase immunity and improve anti-inflammatory, and ... immune function response assessed in the preclinical research were significantly reduced. Results are ...
(Date:7/22/2018)... ... 2018 , ... Mitotech S.A, a Luxembourg based clinical stage ... clinical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will fund ... the first Phase 3 study starting as early as Fall 2018. , ...
Breaking Biology Technology:
(Date:8/7/2018)... ... August 06, 2018 , ... Passersby can’t help ... Southern Illinois University Edwardsville’s University Park. SIUE students are working the “Feedstock Diversity ... These three feedstocks represent conventional biofuels production, advanced biofuels production and cellulosic biofuels ...
(Date:8/7/2018)... BOSTON and SOUTH JORDAN, Utah (PRWEB) , ... August 07, 2018 ... ... communications and collaboration solutions, announced today their new CT Cloud Voice and SIP solutions. ... cloud delivering a scalable and secure, quality voice solution that is far superior to ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... to pharmaceutical and biotech companies, today announced that Mark Jara, principal of the ... people in the life sciences industry. Individuals named to PharmaVOICE 100 are leaders ...
Breaking Biology News(10 mins):